• Customer Care
  • (888) 123-4567

Promoting Human Health
and Well Being

Our Science

Merging our understanding of immune therapy with cutting-edge discoveries of how the microbiome functions, Rise is developing targeted immunotherapy drugs to treat a broad range of clinical indications.


We design immunological-based drugs to treat chronic diseases including autoimmunity, cancer, and infection.

Read more


Our understanding of microbiome science drives novel target identification and innovative drug design.

Read more
Synthetic Biology

Synthetic Biology

We use our proprietary oral biologics delivery technology to engineer novel immunological-directed cellular products.

Read more

Our Capabilities


Synthetic Biology Medicine

As a foundational technology, Rise Therapeutics has developed the innovative and proprietary Tripartite X (TPX) drug delivery platform that embraces synthetic biology-based approaches to enable oral delivery of targeted biologic therapy.



Our clinical GMP drug production capabilities for microbial-based products including Live Biotherapeutic Products (LBPs) enables rapid and efficient translation of innovative bench discoveries towards commercialization.

Our Pipeline

At Rise Therapeutics, our product development focus, in-house clinical GMP manufacturing capabilities, and drug development experience enables us to pursue rapid and efficient novel drug development from innovative laboratory discoveries.

Our Team

Gary Fanger, PHDFounder, President & CEO
Gary Fanger, PHD
Sathya Janardhanan, MS VP of Manufacturing
Sathya Janardhanan, MS

Interested in working with Us?

Become a Partner

Rise Therapeutics is interested in evolving key partnerships with leading academic, biotechnology, and pharmaceutical groups that share our interest and commitment to develop innovative new medicines.

Read more

Join Our Team

We are always looking for extraordinary people with exceptional creativity and enthusiasm. In our collaborative, high performing, and entrepreneurial environment, we work as a team to investigate life saving products and treatments.

Read more

Our News

Rockville, MD. Rise Therapeutics announced today that it has received funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institute of Health’s (NIH) to support proof-of-concept clinical testing of their lead therapeutic candidate, R-3750. R-3750 is synthetic biology-based immune cellular medicine being developed for the treatment of Inflammatory Bowel Disease (IBD). 

Rockville, MD. Rise Therapeutics announced today that they have successfully initiated operations of their GMP manufacturing facility based in Rockville, MD.  Funding to help set up this GMP manufacturing operation came from the National Institute of Health (NIH) Commercialization Readiness Pilot (CRP) Program Grant, which assists small businesses with technical assistance and late-stage development projects that are not typically supported by SBIR and STTR Phase II and Phase IIB grants. Launching of operations for this facility was also supported by the financial contributions of the Montgomery County Economic Development Corporation.  

Rockville, MD. Rise Therapeutics, a company that develops innovative immune therapies, announced today that it initiated a new program to develop a novel, immunologically enhanced microbiome drug for the treatment of cancer. This product candidate, R-5780, engages key immune pathways regulated by the microbiome to enhance the effectiveness of immune checkpoint inhibitor (ICI) therapy to treat cancer. Coinciding with the timing of this release, Rise has secured funding to support key product development initiatives for the program.